# 2025年12月28日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 蛋白质组与基因组联合特征揭示HER2低表达乳腺癌的亚型特异性治疗潜力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41454718)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41454718
**DOI：** 10.1002/advs.202513086

### 第一部分 原文与翻译

**英文原标题：** Proteogenomic Characterization Reveals Subtype-Specific Therapeutic Potential for HER2-Low Breast Cancer.

> **英文摘要：**
> The molecular heterogeneity and distinct features of HER2-low breast cancer are poorly understood, limiting their precise management. To address this issue, longitudinal multiomic profiling of HER2-low breast cancer is performed, including genomics, transcriptomics, proteomics, lactylomics, and phosphoproteomics, using 250 well-characterized samples, and identified three proteomic subtypes: PS1 (estrogen response signaling enriched), PS2 (angiogenesis enriched), and PS3 (proliferation enriched and HER2-high like). These three proteomic subtypes have distinct features and potential therapeutic strategies, namely, endocrine therapy, antiangiogenic therapy, and anti-HER2 therapy, and are validated in external datasets and PDO models. In addition, a detailed description of the genomic characteristics and a map of the lactate modification landscape of HER2-low breast cancer are provided. This research provides complementary information, reveals the molecular characteristics of HER2-low breast cancer, and suggests potential precise therapeutic strategies for patients with this type of cancer.

> **中文摘要：**
> HER2低表达乳腺癌的分子异质性及其独特特征尚不清晰，这限制了其精准管理。为解决这一问题，研究者对HER2低表达乳腺癌进行了多组学纵向分析，包括基因组学、转录组学、蛋白质组学、乳酰化组学及磷酸化蛋白组学，利用250例经过充分表征的样本，鉴定出三种蛋白质组亚型：PS1（富集雌激素反应信号）、PS2（富集血管生成信号）和PS3（富集增殖信号并类似HER2高表达型）。这三种蛋白质组亚型具有不同的特征及潜在治疗策略，分别对应于内分泌治疗、抗血管生成治疗和抗HER2治疗，并在外部数据集和类器官模型中得到验证。此外，研究还详细描述了HER2低表达乳腺癌的基因组特征，并绘制了乳酸修饰图谱。该研究为HER2低表达乳腺癌提供了互补性分子信息，揭示了其分子特征，并提出了潜在的精准治疗策略。

### 第二部分 AI 大师评价

该研究以多组学综合分析为核心，系统描绘了HER2低表达乳腺癌的分子景观，并首次提出其可分为三种具有特异信号富集特征的蛋白质组亚型。工作在样本量和分层验证上具有较强的说服力，展现出显著的临床转化潜力。研究创新性地将乳酰化修饰和多组学整合引入HER2低表达亚型研究，为精准分型与靶向治疗提供了新的思路。其局限可能在于部分亚型疗效验证尚需更多临床证据。

---

## 2. STING激动剂修饰的肿瘤靶向光敏剂通过重塑癌相关成纤维细胞增强胰腺癌光免疫治疗效能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41454716)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41454716
**DOI：** 10.1002/advs.202520547

### 第一部分 原文与翻译

**英文原标题：** STING Agonist-Modified Tumor Targeting Photosensitizer Remodels Cancer-Associated Fibroblasts to Potentiate Photoimmunotherapy in Pancreatic Cancer.

> **英文摘要：**
> Pancreatic cancer (PC) features dense stromal barriers and profound immune exclusion, rendering it largely unresponsive to immunotherapy. Here, we present ICyM2, a carrier-free and esterase-responsive nanoaggregate rationally designed by covalently linking the mitochondria-targeting photosensitizer ICyOH with the non-nucleotide STING agonist MSA-2. This single-molecule construct enables high drug loading, uniform nanoaggregate formation, and preferential tumor accumulation, thereby minimizing hepatic off-target toxicity while allowing spatiotemporally controlled activation in the tumor microenvironment. Upon intratumoral activation, ICyOH disrupts cancer-associated fibroblast (CAF)-mediated stromal barriers and triggers immunogenic cell death (ICD), which facilitates deep penetration of MSA-2. Subsequently, MSA-2 amplifies ICD-derived antigenic signaling, activates the STING pathway, promotes dendritic cell maturation, reprograms macrophages toward an M1-like phenotype, and enhances cytotoxic T-cell infiltration. In vivo, ICyM2 elicits potent tumor regression, establishes durable immune memory that suppresses lung metastasis, and converts immunologically "cold" tumors into "hot." Moreover, ICyM2 synergizes with PD-1 blockade to further strengthen antitumor immunity without observable systemic toxicity. Collectively, ICyM2 integrates stromal remodeling and immune activation within a single, carrier-free platform, providing a clinically translatable photo-immunotherapeutic strategy to overcome stromal and immune resistance in pancreatic cancer.

> **中文摘要：**
> 胰腺癌（PC）具有致密的基质屏障和显著的免疫排斥，因此对免疫治疗大多不敏感。本研究提出了一种名为ICyM2的无载体、酯酶响应型纳米聚集体，通过将线粒体靶向光敏剂ICyOH与非核苷类STING激动剂MSA-2共价连接而理性设计。该单分子结构实现了高药物负载、均一的纳米聚集和优先的肿瘤富集，从而在肿瘤微环境中实现时空可控的激活，同时最大限度减少肝脏的非靶向毒性。经肿瘤内激活后，ICyOH可破坏由癌相关成纤维细胞（CAF）介导的基质屏障，并诱导免疫原性细胞死亡（ICD），促进MSA-2的深层渗透。随后，MSA-2放大源自ICD的抗原信号，激活STING通路，促进树突状细胞成熟，使巨噬细胞向M1样表型重编程，并增强细胞毒性T细胞浸润。在体内，ICyM2可引发显著的肿瘤回缩，建立持久的免疫记忆以抑制肺转移，并将免疫学“冷”肿瘤转化为“热”肿瘤。此外，ICyM2与PD-1阻断联用可进一步增强抗肿瘤免疫，而未观察到系统性毒性。总体而言，ICyM2在单一无载体平台中整合了基质重塑与免疫激活，为克服胰腺癌中的基质与免疫耐受提供了一种具有临床转化潜力的光免疫治疗策略。

### 第二部分 AI 大师评价

该研究通过设计ICyM2这一无载体光敏-STING激动剂共价结合分子，实现了胰腺癌中特有致密基质与免疫抑制微环境的双重调控。研究显示，ICyM2在光激活后不仅破坏成纤维细胞屏障并诱导免疫原性细胞死亡，还能激活STING通路，增强抗肿瘤免疫反应。体内实验证实其可显著抑制肿瘤生长并与PD-1抑制联合产生协同效应。该工作创新性地将基质重塑与免疫激活整合于单一体系，具有重要的临床应用潜力，但仍需进一步研究其长期安全性与跨肿瘤泛化效果。

---

## 3. 具有双酶模拟活性的免疫调节性纤维支架可预防术后肿瘤复发

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41454708)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41454708
**DOI：** 10.1002/advs.202519431

### 第一部分 原文与翻译

**英文原标题：** Immunomodulatory Fibrous Scaffold with Dual Enzyme-Mimic Activities Prevents Postsurgical Tumor Recurrence.

> **英文摘要：**
> Surgical resection remains the frontline treatment for solid tumors. However, postsurgical recurrence driven by residual tumor cells and an immunosuppressive microenvironment continues to challenge long-term survival. Here, we propose an implantable fibrous scaffold functionalized with MnO nanozymes to prevent tumor recurrence. The dual enzyme-mimic activities of the MnO nanozymes endow the scaffold with immunomodulatory functions. On one hand, the MnO nanozymes with peroxidase-like activity catalyze the formation of cytotoxic hydroxyl radicals to trigger immunogenic cell death and antigen release. On the other hand, the catalase-like activity helps alleviate hypoxia by decomposing HO to O, thereby reprogramming macrophages toward a pro-inflammatory M1 phenotype. Concurrently, the released Mn ions serve as a potent immune adjuvant, promoting immune cell recruitment and activation. The coordinated immunomodulatory cascade enables the scaffold to establish a sustained local immune niche. Both in vitro and in vivo evaluations confirm that this MnO-functionalized scaffold elicits robust antitumor immunity, effectively preventing postsurgical recurrence without exogenous immunostimulants. This work highlights a material-based immunotherapeutic strategy that leverages the intrinsic catalytic and immunomodulatory properties of nanozymes to engineer bioactive scaffolds for postoperative cancer treatment.

> **中文摘要：**
> 外科切除仍然是实体肿瘤的一线治疗手段。然而，由残留肿瘤细胞和免疫抑制性微环境驱动的术后复发，仍然对长期生存构成挑战。在此，我们提出一种经 MnO 纳米酶功能化的可植入纤维支架，用以预防肿瘤复发。MnO 纳米酶的双酶模拟活性赋予该支架免疫调节功能。一方面，具有过氧化物酶样活性的 MnO 纳米酶催化生成细胞毒性羟基自由基，从而诱导免疫原性细胞死亡并促进抗原释放。另一方面，具有催化酶样活性的 MnO 纳米酶通过分解过氧化氢生成氧气，帮助缓解缺氧，从而将巨噬细胞重新编程为促炎性的 M1 表型。同时，释放的 Mn 离子作为强效免疫佐剂，促进免疫细胞的募集与活化。这一协调的免疫调节级联反应使支架能够建立持久的局部免疫生态位。体内外实验均证实，该 MnO 功能化支架可诱导强大的抗肿瘤免疫反应，在无需外源免疫刺激剂的情况下有效预防术后复发。本研究突出了基于材料的免疫治疗策略，利用纳米酶的内在催化和免疫调节特性，构建用于术后癌症治疗的生物活性支架。

### 第二部分 AI 大师评价

本研究旨在通过开发具有双酶模拟功能的 MnO 纳米酶功能化纤维支架，实现术后肿瘤复发的预防。作者利用纳米酶的过氧化物酶样和催化酶样活性，双重调控肿瘤免疫微环境，既诱导免疫原性细胞死亡又缓解缺氧并重塑巨噬细胞表型。体内外实验均验证了该材料在不依赖外源免疫刺激的情况下可有效激活抗肿瘤免疫反应。该工作结合材料科学与免疫治疗的交叉创新，为术后局部抗复发治疗提供了新型免疫材料途径，但仍需进一步评估其长期生物安全性与临床转化可行性。

---

## 4. CD147/Basigin：从整合型分子枢纽到可转化治疗靶点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41454696)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41454696
**DOI：** 10.1002/advs.202518884

### 第一部分 原文与翻译

**英文原标题：** CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target.

> **英文摘要：**
> CD147 (Basigin/EMMPRIN), a multifunctional member of the immunoglobulin superfamily (IgSF), is a critical regulator of tumor progression, immune modulation, and metabolic adaptation. Under physiological conditions, it acts as a dynamic scaffold, interacting with monocarboxylate transporters (MCTs), integrins, and cyclophilin A (CyPA) to orchestrate spermatogenesis, embryo implantation, and neural network function. Pathological overexpression of CD147 induces the secretion of matrix metalloproteinases (MMPs), epithelial-mesenchymal transition (EMT), metabolic reprogramming, and immune evasion, functioning as an independent prognostic biomarker in multiple malignancies. Beyond oncology, CD147 is exploited as an entry receptor for pathogens, including SARS‑CoV‑2, HIV‑1, Plasmodium falciparum, and contributes mechanistically to cardiovascular, autoimmune, and neurodegenerative diseases. Notably, CD147 acts as a fundamental "Energy-Structure Coupler," coordinating metabolic flux (via MCTs) with morphogenetic plasticity (via integrins/MMPs) to maintain cellular homeostasis. This review summarizes current insights into CD147's molecular structure, isoforms, post-translational modifications, and signaling pathways, highlighting its pivotal roles across cancer, infection, autoimmunity, and cardiovascular disease. Finally, we discuss challenges such as the "specificity paradox" and propose emerging strategies to exploit CD147 as a precision biomarker and therapeutic target across diverse diseases.

> **中文摘要：**
> CD147（亦称Basigin或EMMPRIN）是免疫球蛋白超家族（IgSF）的多功能成员，是肿瘤进展、免疫调控和代谢适应的关键调节因子。在生理条件下，它作为一个动态支架，与单羧酸转运体（MCTs）、整合素以及环孢素A（CyPA）相互作用，从而协调精子发生、胚胎着床和神经网络功能。在病理状态下，CD147的过度表达会诱导基质金属蛋白酶（MMPs）的分泌、上皮-间质转化（EMT）、代谢重编程和免疫逃逸，并在多种恶性肿瘤中作为独立的预后生物标志物。除肿瘤学外，CD147也被多种病原体（包括SARS‑CoV‑2、HIV‑1和恶性疟原虫）利用为入侵受体，并在心血管、自身免疫及神经退行性疾病中发挥机制性作用。值得注意的是，CD147作为一个基础性的“能量-结构耦合器”，通过MCTs协调代谢通量，通过整合素/MMPs调节形态可塑性，从而维持细胞稳态。本综述总结了有关CD147分子结构、同种型、翻译后修饰及信号通路的最新认识，强调其在癌症、感染、自身免疫和心血管疾病中的关键作用。最后，文章讨论了如“特异性悖论”等挑战，并提出了将CD147作为精准生物标志物和治疗靶点的新策略。

### 第二部分 AI 大师评价

本文系统综述了CD147在肿瘤、感染、自身免疫及心血管疾病中的关键生物学作用，提出其作为能量与结构耦合枢纽的概念，揭示其在代谢与细胞行为间的整合功能。研究的创新性在于从系统生物学层面重新定义CD147的分子枢纽地位，并探讨其作为精准医学靶点的可行性。文章还指出“特异性悖论”等转化研究难题，为未来药物设计和靶点验证提供了思路。总体而言，该综述在机制整合与临床转化之间建立了重要桥梁。

---

## 5. 低水平YTHDC1表达通过上调FSCN1促进核内F-肌动蛋白形成并促进TMZ耐药性胶质母细胞瘤中DNA双链断裂修复。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41454694)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41454694
**DOI：** 10.1002/advs.202513632

### 第一部分 原文与翻译

**英文原标题：** Low YTHDC1 Expression Upregulates FSCN1 to Promote Nuclear F-Actin Formation and Facilitate Double-strand DNA Breaks Repair in TMZ-Resistant Glioblastoma.

> **英文摘要：**
> Glioblastoma (GBM) is an aggressive and recurrent malignancy with a poor prognosis. Although temozolomide (TMZ) is a cornerstone of GBM treatment, its efficacy is often compromised by inherent or acquired resistance, underscoring the urgent need to uncover molecular mechanisms, discover new therapeutic targets, and develop innovative treatment strategies. In this study, we found an increased formation of filamentous actin (F-actin) within the nuclei of TMZ-resistant GBM cells. We also showed that overexpression of FSCN1 in TMZ-resistant GBM cells promotes F-actin formation and facilitates the repair of DNA double-strand breaks (DSBs). Further investigation revealed a marked decrease in the expression of YTHDC1 in TMZ-resistant GBM cells, which regulates FSCN1 through m6A modification. Additionally, FSCN1 activates the CDC42/N-WASP/Arp2/3 signaling pathway by recruiting FGD1 to activate CDC42, which drives nuclear F-actin formation. Importantly, combining the FSCN1 inhibitor NP-G2-044, with TMZ therapy resulted in stronger anti-tumor effects both in vitro and in vivo. In conclusion, the study demonstrates that nuclear F-actin formation in GBM promotes DSB repair and reveals that targeting FSCN1 with NP-G2-044 could be a promising strategy for enhancing treatment outcomes and improving the prognosis for GBM patients.

> **中文摘要：**
> 胶质母细胞瘤（GBM）是一种侵袭性强且易复发的恶性肿瘤，预后不良。尽管替莫唑胺（TMZ）是GBM治疗的基石，但其疗效常因内在或获得性耐药而受限，这凸显了迫切需要揭示分子机制、发现新的治疗靶点并开发创新的治疗策略。在本研究中，我们发现TMZ耐药性GBM细胞核内的丝状肌动蛋白（F-肌动蛋白）形成显著增加。我们还发现，在TMZ耐药性GBM细胞中过表达FSCN1可促进F-肌动蛋白形成并促进DNA双链断裂（DSB）的修复。进一步研究显示，TMZ耐药性GBM细胞中YTHDC1的表达显著降低，而YTHDC1通过m6A修饰调控FSCN1。此外，FSCN1通过募集FGD1激活CDC42，从而激活CDC42/N-WASP/Arp2/3信号通路，驱动核内F-肌动蛋白的形成。重要的是，将FSCN1抑制剂NP-G2-044与TMZ治疗联合使用，无论在体外还是在体内实验中均表现出更强的抗肿瘤效应。总之，本研究表明，GBM中核内F-肌动蛋白的形成促进了DSB修复，并揭示通过NP-G2-044靶向FSCN1可能是一种改善治疗效果和预后的有前景策略。

### 第二部分 AI 大师评价

本研究揭示了YTHDC1低表达与FSCN1上调在TMZ耐药性胶质母细胞瘤中的关键作用，阐明了其通过CDC42/N-WASP/Arp2/3通路促进核内F-肌动蛋白形成和DNA双链断裂修复的机制。研究设计系统，从分子机制到药物干预均有验证，创新性体现在将FSCN1抑制剂NP-G2-044与TMZ联合治疗的新思路。其发现为耐药性GBM治疗提供了潜在靶点。然而，机制验证仍需在更多临床样本中进一步确认。

---

## 6. 超声增强脂质体前药克服儿科实体瘤治疗中的年龄相关生物分布差异

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41454690)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41454690
**DOI：** 10.1002/advs.202513148

### 第一部分 原文与翻译

**英文原标题：** Ultrasound-Boosted Liposomal Prodrug Overcomes Age-Associated Biodistribution Disparity in Pediatric Solid Tumor Therapy.

> **英文摘要：**
> Clinical adoption of nanodrugs for pediatric cancer is hindered by age-associated disparities, with unclear mechanisms limiting nanotherapeutics for childhood solid tumors. Here, we originally find that the in vivo biodistribution of nanocarriers shows marked age differences: juvenile tumor-bearing mice have worse off-target distribution than adults, due to vigorous neovascular proliferation in normal tissues and heightened macrophage phagocytosis in liver and spleen. To address this challenge, an ultrasound-activated liposomal prodrug (CSCPTL) is designed to overcome age-related disparities in off-target distribution. CSCPTL is composed of a camptothecin-lipid prodrug conjugate (SCPT) containing the reactive oxygen species (ROS)-cleavable thioketal linker, a sonosensitizer (chlorin e6, Ce6)-modified lipid, and other commercially available lipids. Upon intravenous injection, the inactive SCPT exerts minimal pharmacological effects on healthy cells. Conversely, once CSCPTL reaches the tumor site and is internalized by cancer cells, ultrasound irradiation activates Ce6 rapidly to generate massive ROS, which cleaves the thioketal linker to release active camptothecin to induce cell apoptosis. CSCPTL showed potent antitumor efficacy in juvenile hepatoblastoma models, showing superior biocompatibility and no side effects, compared with clinically approved nanodrugs such as Abraxane, Doxil, and Onivyde. This study highlights age-related off-target issues and offers a promising ultrasound-controlled strategy for childhood solid tumors.

> **中文摘要：**
> 纳米药物在儿科癌症临床应用中的推广受限于年龄相关差异，其机制尚不明确，从而限制了儿童实体瘤的纳米治疗。在本研究中，我们首次发现纳米载体在体内的生物分布存在显著的年龄差异：带瘤幼年小鼠的非靶向分布较成年小鼠更差，这主要归因于正常组织中新生血管的旺盛增殖及肝脾中巨噬细胞吞噬活动的增强。为应对这一挑战，本研究设计了一种超声激活的脂质体前药（CSCPTL），旨在克服年龄相关的非靶向分布差异。CSCPTL 由含有活性氧（ROS）可裂解硫缩酮连接子的喜树碱-脂质前药偶联物（SCPT）、经超声敏剂（叶绿素 e6，Ce6）修饰的脂质及其他商业可得脂质组成。经静脉注射后，失活的 SCPT 对健康细胞几乎无药理作用。相反，当 CSCPTL 到达肿瘤部位并被癌细胞内吞后，超声照射可迅速激活 Ce6 产生大量 ROS，从而裂解硫缩酮连接子，释放活性喜树碱以诱导细胞凋亡。在幼年肝母细胞瘤模型中，CSCPTL 显示出强效的抗肿瘤活性，具有优异的生物相容性且无副作用，与临床获批的纳米药物（如 Abraxane、Doxil 和 Onivyde）相比表现更优。本研究揭示了年龄相关的非靶向问题，并提出了一种有望应用于儿童实体瘤的超声可控治疗策略。

### 第二部分 AI 大师评价

本研究针对儿科癌症纳米药物在不同年龄间存在的生物分布差异，创新性地开发了超声触发型脂质体前药系统 CSCPTL。其通过 ROS 可裂解结构及超声激活的靶向释放机制，有效减少了非靶向分布并显著增强了幼年肿瘤模型中的治疗效果。研究结果为解决儿科纳米药物在体内分布不均的问题提供了新思路。其特色在于将声敏剂与前药设计有机结合，实现精准的药物激活；但未来仍需在大动物模型及临床安全性上进一步验证。

---

## 7. 多组学分析揭示肿瘤内细菌如何塑造胃癌的免疫微环境

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41454622)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41454622
**DOI：** 10.1093/gpbjnl/qzaf132

### 第一部分 原文与翻译

**英文原标题：** Multiomics Analysis Reveals How Intratumoral Bacteria Shape the Immune Microenvironment in Gastric Cancer.

> **英文摘要：**
> The occurrence and progression of gastric cancer (GC) are closely associated with dysbiosis of the gastric microbiota and alteration in host microenvironments. However, the interaction between intratumoral bacteria and gastric microenvironments remains incompletely understood. In this study, we characterized the biological profiles of intratumoral bacteria, metabolome, and proteome in 20 GC tumors and paired non-tumor tissues, in combination with six independent datasets (comprising 497 gastric tissue biopsies and 554 normal tissues), as well as mucosal tissues from 10 individuals without GC. We found that the diversity and richness of gastric microbiota were significantly higher in tumor tissues than in non-tumor tissues. In contrast, the lowest biodiversity, at both the genus and species levels, was found in the microbiota of individuals without GC. Specifically, tumors were enriched with Bacteroides thetaiotaomicron, Lactobacillus parabrevis, Brevundimonas nasdae, and Brevundimonas vesicularis. We also identified 39 human immunity-related proteins, particularly in the tryptophan metabolic pathway, which were differentially expressed across various microenvironments (tumor and non-tumor). Furthermore, we found that several pathways involved in the human immune system and associated with the gastric microbiota, such as thiazole biosynthesis II, pyrimidine deoxyribonucleoside salvage, superpathway of pyrimidine deoxyribonucleoside salvage, and superpathway of heme biosynthesis from uroporphyrinogen-III, hold potential as biomarkers for early detection of GC. Our results provide a comprehensive framework for investigating the complex interactions between the tumor immune microenvironment and intratumoral bacterial community.

> **中文摘要：**
> 胃癌（GC）的发生和进展与胃部微生物群失衡以及宿主微环境的改变密切相关。然而，肿瘤内细菌与胃部微环境之间的相互作用仍未被完全阐明。在本研究中，我们分析了20例胃癌肿瘤及其配对的非肿瘤组织中的肿瘤内细菌群、代谢组和蛋白质组特征，并整合了六个独立数据集（包含497个胃组织活检样本和554个正常组织），以及来自10名无胃癌个体的黏膜组织。结果显示，肿瘤组织中胃部微生物群的多样性和丰富度显著高于非肿瘤组织。相反，在无胃癌个体的微生物群中，无论在属水平还是种水平均显示出最低的生物多样性。具体而言，肿瘤组织中富集了地中海拟杆菌（Bacteroides thetaiotaomicron）、副短乳杆菌（Lactobacillus parabrevis）、纳斯德短褐杆菌（Brevundimonas nasdae）和囊泡短褐杆菌（Brevundimonas vesicularis）。此外，我们鉴定出39种与人类免疫相关的蛋白，特别是在色氨酸代谢通路中，在不同微环境（肿瘤与非肿瘤）间表现出差异性表达。进一步分析发现，一些与胃部微生物群相关并参与人类免疫系统的通路，如噻唑生物合成II、嘧啶脱氧核苷拯救途径、嘧啶脱氧核苷拯救超级通路和从尿卟啉原III合成血红素的超级通路，具有作为胃癌早期检测生物标志物的潜力。我们的结果为探索肿瘤免疫微环境与肿瘤内细菌群之间的复杂相互作用提供了系统的研究框架。

### 第二部分 AI 大师评价

该研究以多组学整合方法揭示了肿瘤内细菌与胃癌免疫微环境之间的互作机制。通过结合菌群、代谢组与蛋白质组数据及独立外部数据集，全面解析了细菌组成差异和免疫相关通路变化。研究发现肿瘤组织中微生物多样性上升，特定细菌丰度增加，并揭示了与免疫通路相关的关键代谢特征。其创新在于多维度联用的数据整合与潜在生物标志物识别，但样本规模与功能验证仍需后续研究扩展。

---

## 8. 长读长测序揭示口腔鳞状细胞癌中的重复扩增与大型结构变异。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41454621)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41454621
**DOI：** 10.1093/gpbjnl/qzaf133

### 第一部分 原文与翻译

**英文原标题：** Long-read Sequencing Reveals Repeat Expansions and Large Structural Variants in Oral Squamous Cell Carcinoma.

> **英文摘要：**
> Previous genomic studies have predominantly analyzed oral squamous cell carcinoma (OSCC) in conjunction with other head and neck squamous cell carcinomas (HNSCC), constraining our comprehension of OSCC-specific structural variants (SVs). Here, we performed long-read whole-genome sequencing on 16 paired OSCC tumor and blood samples to elucidate the biological functions of somatic SVs. We identified a total of 5775 high-confidence somatic SVs, including five recurrent simple repeat expansions (SREs). Notably, one SRE located within the promoter region of the OBI1 gene is present in 45% of OSCC samples. Knocking out this SRE in the HSC4 cell line significantly reduces the expression of OBI1, resulting in decreased proliferative and migratory capacities compared to wild-type cells. Furthermore, we found that the frequently amplified region 11q13 in HNSCC is prone to large-scale somatic SVs, affecting the expression of ANO1, FADD, and CTTN, thereby confirming the association of SVs in this region with OSCC development. Our study provides novel insights into the role of somatic SVs in OSCC, especially with respect to SREs and large-scale SVs in critical genomic regions, thereby enhancing our comprehension of the molecular pathogenesis of OSCC.

> **中文摘要：**
> 以往的基因组学研究主要将口腔鳞状细胞癌（OSCC）与其他头颈部鳞状细胞癌（HNSCC）共同分析，从而限制了我们对OSCC特异性结构变异（SVs）的理解。在本研究中，我们对16对OSCC肿瘤与血液样本进行了长读长全基因组测序，以阐明体细胞SV的生物学功能。我们共鉴定出5775个高置信度的体细胞SV，其中包括5个复发性简单重复扩增（SREs）。值得注意的是，一个位于OBI1基因启动子区域内的SRE在45%的OSCC样本中出现。敲除HSC4细胞系中的该SRE显著降低了OBI1的表达，与野生型细胞相比，其增殖与迁移能力明显下降。此外，我们发现HNSCC中常见的扩增区域11q13易发生大规模体细胞SV，这些变异影响ANO1、FADD和CTTN的表达，从而证实了该区域的SV与OSCC发生发展的关联。本研究为体细胞SV在OSCC中的作用提供了新的见解，特别是在关键基因组区域内的SRE和大规模SV方面，进一步加深了我们对OSCC分子发病机制的理解。

### 第二部分 AI 大师评价

本研究旨在利用长读长全基因组测序技术解析口腔鳞状细胞癌中特有的结构变异。作者通过对16对肿瘤及血液样本的分析，发现了数千个高置信度体细胞结构变异，并揭示了OBI1基因启动子区域的重复扩增与肿瘤细胞表型之间的功能联系。研究同时证实了11q13区的大型结构变异与关键癌基因表达异常的相关性。整体而言，该研究在揭示OSCC分子结构变异谱及其功能意义方面具有重要创新，但样本量相对有限，仍需在更大人群中验证。

---

## 9. 更正：化疗药物对肝脏微环境的影响——奥沙利铂营造促转移微环境。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41454417)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41454417
**DOI：** 10.1186/s13046-025-03604-3

### 第一部分 原文与翻译

**英文原标题：** Correction: Impact of chemotherapeutic agents on liver microenvironment: oxaliplatin create a pro-metastatic landscape.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该文为对先前研究的更正说明，聚焦化疗药物奥沙利铂对肝脏微环境的影响及其在转移促进中的潜在作用。虽然原文未提供摘要，但标题暗示研究强调药物治疗与肿瘤微环境交互的重要性。此主题具有较高的临床与转化价值，提示在抗癌治疗中需关注化疗的系统性影响。更正性声明也体现研究团队对数据准确性的严谨态度。

---

## 10. 更正：RNA结合蛋白CCDC137通过DGCR8在mRNA定位中的新型非典型功能激活AKT信号并促进肝细胞癌进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41454394)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41454394
**DOI：** 10.1186/s13046-025-03612-3

### 第一部分 原文与翻译

**英文原标题：** Correction: RNA‑binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non‑canonical role of DGCR8 in mRNA localization.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要提供。

### 第二部分 AI 大师评价

本更正文章涉及CCDC137在肝细胞癌中通过AKT信号通路起促进作用的研究，尤其强调DGCR8在mRNA定位中的非典型功能。研究显示，RNA结合蛋白CCDC137可能通过这一新颖机制驱动肿瘤进展。尽管本条目为更正类型而非完整研究，但其主题揭示了RNA定位与信号转导之间潜在的交叉机制，具有重要科研启示。

---

## 11. 非典型NOTCH1信号通路调控具有稳定耐药性的休眠肺癌细胞对铁死亡的易感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41453945)
**期刊：** Cell death & disease
**PMID：** 41453945
**DOI：** 10.1038/s41419-025-08355-9

### 第一部分 原文与翻译

**英文原标题：** Non-canonical NOTCH1 signaling regulates ferroptosis vulnerability in dormant lung cancer cells with stable resistance.

> **英文摘要：**
> Non-genetic resistance of cancer remains poorly understood in clinical research and practice. To better understand resistant cancer cell heterogeneity, we isolated a novel riboflavinNOTCH1 population from cisplatin-naïve and -resistant lung cancer cell lines and patient specimens with or without immunotherapy and chemotherapy. This population was also identified as SLC52A2 (one of the riboflavin transporters)NOTCH1 cells in single-cell RNA sequencing (scRNA-seq) data derived from advanced lung tumors before therapy. Despite its therapy-naïve origin, the population, designated as stably resistant cancer cells (SRCC), exhibited the epithelial state, innate and stable resistance to therapy (chemotherapy, targeted therapy and immunotherapy), cell dormancy, elevated reactive oxygen species (ROS), and anti-apoptotic and anti-ferroptotic survival. These cellular and molecular characteristics distinguished SRCC from other resistant populations, including cancer stem-like cells (CSC), epithelial-mesenchymal transition (EMT) cells, and drug-tolerant persisters (DTP). The non-canonical NOTCH1 pathway, but not the inactivated canonical NOTCH1 pathway, played a critical role in the resistance of SRCC. Specifically, it modulates cell cycle, iron metabolism, EMT, and ferroptosis vulnerability in SRCC at the transcriptional level. It also controls the initiation of ferroptosis in lysosomes via a posttranslational NOTCH1-AKT-BAX axis. Inhibition of the non-canonical NOTCH1 pathway re-sensitizes these dormant and resistant cells to cisplatin-induced cell death in vitro and in vivo, including ferroptosis, apoptosis, and necroptosis. Our study contributes to a deeper understanding of cancer resistance and promotes the development of more effective therapeutic strategies against resistant cancer cells.

> **中文摘要：**
> 癌症的非遗传性耐药性在临床研究与实践中仍缺乏深入理解。为更好地阐明耐药癌细胞的异质性，我们从顺铂未经处理和耐药的肺癌细胞系以及患者样本（包括接受或未接受免疫治疗和化疗者）中分离出一种新的核黄素NOTCH1细胞群体。在来自未经治疗的晚期肺癌单细胞RNA测序（scRNA-seq）数据中，该群体也被鉴定为SLC52A2（核黄素转运蛋白之一）NOTCH1细胞。尽管该群体来源于未经治疗的细胞，但被命名为稳定耐药癌细胞（SRCC），表现出上皮状态、对治疗（化疗、靶向治疗及免疫治疗）的先天且稳定的耐药性、细胞休眠、高水平的活性氧（ROS）生成以及抗凋亡和抗铁死亡的生存特征。这些细胞和分子特征使SRCC区别于其他耐药细胞群，如癌症干样细胞（CSC）、上皮-间质转化（EMT）细胞以及耐药持续细胞（DTP）。非典型NOTCH1通路（而非失活的典型NOTCH1通路）在SRCC的耐药性中发挥关键作用。具体而言，它在转录水平上调控SRCC的细胞周期、铁代谢、EMT以及对铁死亡的易感性。此外，该通路还通过转录后NOTCH1-AKT-BAX轴控制溶酶体中铁死亡的启动。抑制非典型NOTCH1通路可在体内外重新使这些休眠且耐药的细胞对顺铂诱导的细胞死亡产生敏感性，包括铁死亡、凋亡和程序性坏死。我们的研究有助于深入理解癌症耐药机制，并推动针对耐药癌细胞的更有效治疗策略的开发。

### 第二部分 AI 大师评价

本研究针对非遗传性癌症耐药的机制进行了深入探索，发现一类具有稳定耐药性的休眠肺癌细胞群（SRCC），并揭示非典型NOTCH1信号通路在其调控铁死亡易感性中的关键作用。作者通过细胞分离、单细胞测序及分子机制分析，阐明了NOTCH1-AKT-BAX轴在溶酶体铁死亡启动过程中的功能。该研究在概念上将非典型信号通路与细胞代谢脆弱性关联，为克服休眠和耐药性癌细胞提供了新策略。其创新性突出，但仍需在临床样本和动态治疗模型中进一步验证。

---

## 12. 光控三甲氧苄胺 PROTAC 靶向 eDHFR 蛋白标签

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41453904)
**期刊：** Nature communications
**PMID：** 41453904
**DOI：** 10.1038/s41467-025-67527-5

### 第一部分 原文与翻译

**英文原标题：** Photocontrolled trimethoprim PROTACs targeting the eDHFR protein tag.

> **英文摘要：**
> Proteolysis targeting chimeric small molecules (PROTACs) offer a strategy for degrading disease-associated proteins or controlling engineered protein tags fused to therapeutic proteins, like chimeric antigen receptors (CARs). New approaches are needed that allow spatiotemporal control of PROTAC activity, restricting degrader activity to targeted cells. Photopharmacology offers a solution by enabling light-mediated spatial control of drug action. Here, we synthesize photocaged and photoswitchable PROTAC molecules and test their regulation of proteins tagged with E. coli dihydrofolate reductase (eDHFR) in tumor and CAR-T cells. Several of the molecules are derived from triazole-linked trimethoprim-PROTACs (TMP-TACtz), that degrade eDHFR fused proteins at picomolar concentrations, show degradation in cells with low cereblon E3 ligase levels, and have little off-target effects. The photocleavable compound, TMP-TAC-PC yields the best light-mediated regulation of CAR T cell cytotoxicity and cytokine secretion. This work introduces photocontrolled, tag-directed degraders for controlling protein expression in tumor cells and CAR T cells.

> **中文摘要：**
> 靶向蛋白水解嵌合小分子（PROTACs）为降解疾病相关蛋白或控制融合于治疗性蛋白（如嵌合抗原受体，CAR）的工程化蛋白标签提供了一种策略。需要新的方法实现 PROTAC 活性的时空调控，从而将降解活性限制在特定靶细胞中。光药理学通过实现光介导的空间性药效控制，提供了一种可行方案。在本研究中，我们合成了光笼化和光开关型 PROTAC 分子，并评估了它们在肿瘤细胞和 CAR-T 细胞中对携带大肠杆菌二氢叶酸还原酶（eDHFR）标签蛋白的调控作用。其中几种分子来源于三唑连接的三甲氧苄胺-PROTAC（TMP-TACtz），这些分子可在皮摩尔级浓度下降解 eDHFR 融合蛋白，在低 cereblon E3 泛素连接酶水平的细胞中也能实现降解，并且几乎无非特异性作用。光可裂解化合物 TMP-TAC-PC 在调控 CAR-T 细胞的细胞毒活性和细胞因子分泌方面表现出最佳的光介导调节效果。本研究提出了一类光控、标签定向的降解剂，用于调节肿瘤细胞和 CAR-T 细胞中的蛋白表达。

### 第二部分 AI 大师评价

本研究旨在开发光控三甲氧苄胺 PROTAC 分子，以实现蛋白降解的时空精准调控。作者通过设计光笼化与光开关型 PROTAC，实现对 eDHFR 标签蛋白的可逆降解，并在肿瘤及 CAR-T 细胞中验证其光响应特性。关键结果显示 TMP-TAC-PC 在 CAR-T 细胞功能调控中具有优异的光依赖效果。该研究创新地将光药理学与 PROTAC 技术结合，为细胞水平的精准蛋白调控提供了新的策略，但其光穿透性及体内应用仍需进一步优化。

---

## 13. PIM激酶抑制削弱经典型霍奇金淋巴瘤中巨噬细胞的促肿瘤与免疫抑制功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41453879)
**期刊：** Cell death & disease
**PMID：** 41453879
**DOI：** 10.1038/s41419-025-08402-5

### 第一部分 原文与翻译

**英文原标题：** PIM kinase inhibition attenuates pro-tumoral and immunosuppressive functions of macrophages in classic Hodgkin lymphoma.

> **英文摘要：**
> Tumor-associated macrophages (TAMs) of classic Hodgkin Lymphoma (cHL) contribute to the development of immunosuppressive tumor microenvironment (TME) and are associated with worse treatment outcomes. However, detailed features, functions and therapeutic vulnerabilities of cHL TAMs remain largely unknown. To address this, we analyzed cHL diagnostic biopsies by Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) and assessed transcriptional, proteomic and metabolic profiles of in vitro TAM models. We show that Reed-Sternberg (RS) cells induce a disease-specific TAM phenotype, characterized by elevated expression of factors involved in chemotaxis, angiogenesis, extracellular matrix remodeling and tumor immune escape. RS cell-conditioned TAMs expressed TGFβ, CCL17 and tryptophan catabolizing enzymes, IDO1 and IL4I1, promoting regulatory T cell recruitment and activation. In addition, we identified the expression of PIM1/2/3 kinases in cHL TAMs and characterized PIMs as critical hubs orchestrating RS-macrophage interactions. Pharmacological PIM blockade attenuated the RS-induced TAM transcriptional program. In established TAMs, PIM inhibition or PROTAC-mediated degradation decreased the expression of multiple factors associated with pro-tumoral TAM functions, including IL8, MMP9, CHI3L1/2, CD206, CD209, PD-L1, CCL17, TGFβ, IL4I1 and IDO1. PIM blockade attenuated TAM-dependent eosinophil chemoattraction, extracellular matrix remodeling, angiogenesis and regulatory T-cell development. Taken together, our study highlights the role of PIMs in the regulation of pathogenic TAM functions in cHL, further supporting the rationale of PIM targeting in this disease.

> **中文摘要：**
> 经典型霍奇金淋巴瘤（cHL）的肿瘤相关巨噬细胞（TAMs）促进了免疫抑制性肿瘤微环境（TME）的形成，并与较差的治疗结果相关。然而，cHL中TAM的详细特征、功能及其治疗易损性仍然知之甚少。为了解决这一问题，我们利用测序法细胞转录组与表位索引（CITE-seq）分析了cHL的诊断性活检样本，同时评估了体外TAM模型的转录组、蛋白质组及代谢特征。我们证明了Reed-Sternberg（RS）细胞可诱导出一种疾病特异性的TAM表型，其特征是趋化、血管生成、细胞外基质重塑与肿瘤免疫逃逸相关因子的高表达。经RS细胞调控的TAM表达TGFβ、CCL17以及色氨酸代谢酶IDO1和IL4I1，从而促进调节性T细胞的募集与活化。此外，我们在cHL TAMs中鉴定到PIM1/2/3激酶的表达，并发现PIM是协调RS细胞与巨噬细胞相互作用的关键枢纽。药理学性PIM阻断可削弱RS诱导的TAM转录程序。在已分化的TAM中，PIM抑制或基于PROTAC的降解可降低多种与促肿瘤TAM功能相关的因子的表达，包括IL8、MMP9、CHI3L1/2、CD206、CD209、PD-L1、CCL17、TGFβ、IL4I1和IDO1。PIM阻断可减弱TAM依赖的嗜酸性粒细胞趋化、细胞外基质重塑、血管生成及调节性T细胞发育。综上所述，本研究揭示PIM在调控cHL中致病性TAM功能中的作用，并进一步支持在该疾病中靶向PIM的治疗策略。

### 第二部分 AI 大师评价

该研究旨在揭示PIM激酶在经典型霍奇金淋巴瘤中调控巨噬细胞致病功能的作用机制。作者结合CITE-seq单细胞转录组、体外蛋白及代谢实验，阐明了RS细胞诱导的TAM呈现独特的促肿瘤和免疫抑制表型。研究发现药理性或PROTAC介导的PIM阻断显著削弱TAM的促进肿瘤功能，提示PIM是潜在的免疫治疗靶点。该工作创新性地揭示了PIM-TAM轴的致病作用，但仍需在动物模型与临床样本中验证其治疗可行性。

---

## 14. SREBP1 介导的脂质生成通过表观遗传重塑促进血管平滑肌细胞的去分化和衰老。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41453868)
**期刊：** Nature communications
**PMID：** 41453868
**DOI：** 10.1038/s41467-025-67534-6

### 第一部分 原文与翻译

**英文原标题：** SREBP1-mediated lipogenesis promotes dedifferentiation and senescence of vascular smooth muscle cells through epigenetic remodeling.

> **英文摘要：**
> Real or simulated microgravity induces a senescence-like modification of carotid artery in both human and animal observations, with the mechanisms not fully elucidated. Here, we aim to elucidate the role of sterol regulatory element-binding protein 1 (SREBP1, encoded by Srebf1) mediated lipogenesis in the process. Pharmacological activation of SREBP1 directly triggers senescence-like transformation in vascular smooth muscle cells (VSMC), while silencing Srebf1 exerts an opposite effect. Mechanistically, SREBP1-mediated lipogenesis upregulates acetyl-CoA pool to increase histone acetylation, modifying the chromatin accessibility which limiting recruitment of SRF/myocardin complexes to CArG boxes of contractile genes and opening the chromatin accessibility of aging genes. Srebf1 knockdown and local delivery of lentivirus or AAV-mediated VSMC specific expressing sh-Srebf1 significantly attenuates the senescence-like transformation of VSMC both in vitro and in vivo. Our findings reveal a previously unrecognized feature of SREBP1-mediated lipogenesis in vascular biology and SM-induced carotid artery remodeling.

> **中文摘要：**
> 真实或模拟的微重力都会在人类和动物观察中引起颈动脉的类衰老样改变，其机制尚未完全阐明。在此，我们旨在阐明由固醇调节元件结合蛋白 1（SREBP1，由 Srebf1 编码）介导的脂质生成在该过程中所起的作用。药理学激活 SREBP1 可直接诱导血管平滑肌细胞（VSMC）发生类衰老样转化，而沉默 Srebf1 则产生相反的效果。在机制上，SREBP1 介导的脂质生成可上调乙酰辅酶 A（acetyl-CoA）库，从而增加组蛋白乙酰化，改变染色质可及性，限制 SRF/myocardin 复合物对收缩基因 CArG 盒的结合，并开放衰老相关基因的染色质可及性。Srebf1 的敲低以及利用慢病毒或 AAV 介导的 VSMC 特异性 sh-Srebf1 局部递送，均可显著减弱 VSMC 的类衰老样转化，无论在体外还是体内均如此。我们的研究揭示了 SREBP1 介导的脂质生成在血管生物学及微重力诱导的颈动脉重塑中的一种先前未被认识的特征。

### 第二部分 AI 大师评价

该研究针对微重力诱导血管老化的未明机制，揭示了 SREBP1 介导的脂质生成在血管平滑肌细胞去分化与衰老中的核心作用。研究通过药理学激活和基因沉默实验，结合体内外验证，系统说明了脂质代谢通过乙酰辅酶 A 增加组蛋白乙酰化从而重塑染色质可及性的机制。结果为血管衰老及微重力相关血管重塑提供了新的代谢-表观遗传联系，具有较强的创新性。其局限性在于主要集中于小鼠和细胞模型，仍需在人体样本中进一步验证。

---

## 15. 证据显示白细胞介素-17C调控白细胞介素-17A的致病性并促进支气管扩张症中的哮喘表型转换

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41453857)
**期刊：** Nature communications
**PMID：** 41453857
**DOI：** 10.1038/s41467-025-67769-3

### 第一部分 原文与翻译

**英文原标题：** Evidence for Interleukin-17C governing interleukin-17A pathogenicity and promoting asthma endotype switching in bronchiectasis.

> **英文摘要：**
> The management of bronchiectasis-asthma overlap (BAO) is an important clinical issue to be addressed. Little is known regarding the endotype of BAO. Here we recruit patients with a primary diagnosis of bronchiectasis and co-existing asthma. The levels of interleukin (IL)-17C are positively correlated with the levels of IL-17A or group 3 innate lymphoid cells (ILC3s) in peripheral blood samples from patients with BAO. An in vivo mouse model of Pseudomonas aeruginosa chronic lower respiratory tract infection followed by ovalbumin-induced asthma shows that IL-17C potentiates IL-17A expression via interacting with IL-17 receptor E in ILC3s. Additionally, ablation of Il17re in mice attenuates ILC3 responses and IL-17A-mediated asthma endotype switching towards neutrophilic asthma driven by P. aeruginosa chronic lower respiratory tract infection. Lastly, impaired epithelial barrier integrity by P. aeruginosa exposure is associated with IL-17C production in vitro. Collectively, our study implicates evidence for IL-17C governing IL-17A pathogenicity and promoting asthma endotype switching in bronchiectasis, implicating IL-17C as a potential therapeutic target for individuals with BAO.

> **中文摘要：**
> 支气管扩张与哮喘重叠（BAO）的管理是一个需要解决的重要临床问题。目前对BAO的分子内型知之甚少。本研究招募了以支气管扩张为主要诊断且伴有哮喘的患者。结果显示，在这些患者的外周血样本中，白细胞介素（IL）-17C的水平与IL-17A或第3型先天性淋巴样细胞（ILC3）的水平呈正相关。在一种体内小鼠模型中，先建立铜绿假单胞菌慢性下呼吸道感染，再诱导卵清蛋白性哮喘，结果表明IL-17C通过与ILC3中的IL-17受体E相互作用，增强了IL-17A的表达。此外，在小鼠中敲除Il17re基因可削弱ILC3反应，并减轻由铜绿假单胞菌慢性感染驱动的IL-17A介导的哮喘内型向中性粒细胞性哮喘的转变。最后，体外实验发现，铜绿假单胞菌暴露导致的上皮屏障完整性受损与IL-17C的产生相关。总体而言，本研究提供了IL-17C调控IL-17A致病性并促进支气管扩张症中哮喘内型转换的证据，提示IL-17C可能是BAO患者的潜在治疗靶点。

### 第二部分 AI 大师评价

该研究聚焦于支气管扩张与哮喘重叠（BAO）患者的免疫学机制，揭示了IL-17C通过作用于ILC3及其受体IL-17RE，从而强化IL-17A的致病作用并驱动哮喘内型转换。研究采用了临床样本检测与体内小鼠模型双重验证，证实IL-17C在支气管扩张相关哮喘中的关键调控作用。此发现为理解BAO免疫内型提供了新框架，并指出IL-17C作为潜在治疗靶点的可能性。研究创新性强，但仍需在临床水平验证IL-17C抑制策略的有效性与安全性。

---

## 16. YTHDF3 抑制干扰素刺激基因（ISG）依赖的抗肿瘤免疫并促进宫颈癌中 HPV 致癌过程。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41453852)
**期刊：** Cell death & disease
**PMID：** 41453852
**DOI：** 10.1038/s41419-025-08188-6

### 第一部分 原文与翻译

**英文原标题：** YTHDF3 suppresses interferon-stimulated gene (ISG)-dependent antitumor immunity and promotes HPV carcinogenesis in cervical cancer.

> **英文摘要：**
> Interferon-stimulated genes (ISGs) serve as evolutionarily conserved mediators of antiviral defense and tumor surveillance. Emerging evidence underscores the non-oncogenic addiction of high-risk human papillomavirus (hrHPV) E6/E7 oncoproteins in maintaining malignant phenotypes and cervical carcinogenesis. Here, we leveraged CRISPR/Cas9-engineered YTHDF3-knockout (YTHDF3) SiHa cells and Ythdf3 mice to dissect the molecular arbiters governing mA-dependent RNA regulation in HPV-driven carcinogenesis. To further elucidate the role of YTHDF3 in HPV-induced immunosuppressive tumor microenvironment (ITME) formation, we demonstrated that YTHDF3, an mA RNA reader, suppresses type I ISGs responses. Notably, elevated mA modification and YTHDF3 protein levels were observed in HPV CCa tissues. Mechanistically, YTHDF3 bound to the mA methylation site of STAT3 mRNA, enhancing its stability and transcription efficiency. This YTHDF3-STAT3 axis repressed ISG (e.g., IRF7) transcription and IFN-α production, thereby compromising antiviral immunity and facilitating HPV E6/E7 persistence. Correspondingly, Ythdf3 mice bearing TC-1 xenografts exhibited a significant reduction in immunosuppressive immune cell infiltration, including Tregs, M2 macrophages, and MDSCs, accompanied by enhanced CD8 T cell activation. Collectively, our findings unveiled that YTHDF3-mediated upregulation of STAT3 suppresses the type I ISG expression, thus promoting HPV carcinogenesis and establishing an ITME. Taken together, our results suggest that targeting the YTHDF3/STAT3/IRF7 axis could be a promising therapeutic strategy against HPV-associated malignancies.

> **中文摘要：**
> 干扰素刺激基因（ISGs）作为进化上保守的介质，参与抗病毒防御和肿瘤监视。新兴证据强调，高危型人乳头瘤病毒（hrHPV）E6/E7 癌蛋白在维持恶性表型和宫颈癌发生过程中存在非致癌性依赖。本文利用 CRISPR/Cas9 技术构建的 YTHDF3 基因敲除 SiHa 细胞以及 Ythdf3 小鼠模型，解析了驱动 HPV 致癌过程中 m⁶A 依赖性 RNA 调控的分子机制。为进一步阐明 YTHDF3 在 HPV 诱导的免疫抑制性肿瘤微环境（ITME）形成中的作用，我们证明 YTHDF3 作为一种 m⁶A RNA 识读蛋白，可抑制 I 型 ISG 的应答。值得注意的是，在 HPV 相关宫颈癌组织中观察到 m⁶A 修饰及 YTHDF3 蛋白水平均明显升高。机制上，YTHDF3 与 STAT3 mRNA 的 m⁶A 甲基化位点结合，从而增强其稳定性和转录效率。该 YTHDF3-STAT3 轴抑制了 ISG（如 IRF7）的转录及 IFN-α 的产生，从而削弱抗病毒免疫，促进 HPV E6/E7 的持续存在。相应地，携带 TC-1 异种移植瘤的 Ythdf3 小鼠表现出免疫抑制性免疫细胞（包括调节性 T 细胞、M2 型巨噬细胞和骨髓来源抑制细胞）浸润显著减少，并伴随 CD8 T 细胞活化增强。综合来看，我们的研究揭示，YTHDF3 介导的 STAT3 上调抑制了 I 型 ISG 的表达，从而促进 HPV 致癌并建立免疫抑制性肿瘤微环境。总体而言，靶向 YTHDF3/STAT3/IRF7 轴可能成为治疗 HPV 相关恶性肿瘤的潜在策略。

### 第二部分 AI 大师评价

本研究聚焦于 YTHDF3 在 HPV 驱动的宫颈癌中的免疫抑制机制，结合基因编辑细胞模型和小鼠实验，系统揭示了 YTHDF3 通过促进 STAT3 mRNA 稳定性和活性而抑制 I 型干扰素信号及抗病毒免疫。研究提出了 YTHDF3/STAT3/IRF7 轴在 HPV 致癌中扮演关键调控角色，深化了对 HPV 相关免疫逃逸机制的理解。创新性在于从 m⁶A RNA 调控层面解释 HPV 致癌的免疫维度，且提出了新的潜在治疗靶点。其局限性主要在于临床验证仍需进一步开展。

---

## 17. 通过超图学习从空间组学揭示组织结构与肿瘤微环境

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41453080)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41453080
**DOI：** 10.1093/gpbjnl/qzaf128

### 第一部分 原文与翻译

**英文原标题：** Unveiling Tissue Structure and Tumor Microenvironment from Spatial Omics by Hypergraph Learning.

> **英文摘要：**
> Spatial omics technologies have revolutionized life sciences by enabling the simultaneous acquisition of biomolecular and spatial information. Identifying spatial patterns is crucial for understanding organ development and tumor microenvironments. However, the emergence of diverse spatial omics resolutions in these technologies has made it challenging to accurately characterize spatial domains at finer resolutions. To address this, we propose HyperSTAR, a hypergraph-based method designed to precisely identify spatial domains across varying resolutions by leveraging higher-order relationships among spatially adjacent tissue programs. Specifically, a gene expression-guided hyperedge decomposition module is introduced to refine the hypergraph structure to accurately delineate spatial domains boundaries. Additionally, a hypergraph attention convolutional neural network is designed to adaptively learn the importance of each hyperedge, enhancing the model's ability to capture complex higher-order relationships within spatially neighboring multi-spots and/or single cells. HyperSTAR outperforms existing graph neural network models in tasks such as uncovering tissue substructures, inferring spatiotemporal patterns, and denoising spatially resolved gene expressions. It effectively handles diverse spatial omics data types and scales seamlessly to large datasets. The method successfully reveals spatial heterogeneity in breast cancer sections, with findings validated through functional and survival analyses of independent clinical data. HyperSTAR represents a significant advancement in spatial omics analysis, representing a robust tool for exploring complex spatial patterns across varying resolutions and data types. Its ability to capture intricate higher-order relationships among spatially neighboring spots/cells makes it an invaluable tool for advancing research in life sciences, particularly in cancer and developmental biology. The toolbox is available at https://github.com/Ringoio/HyperSTAR.

> **中文摘要：**
> 空间组学技术通过实现生物分子信息与空间信息的同步获取，已彻底改变了生命科学研究。识别空间模式对于理解器官发育和肿瘤微环境至关重要。然而，这些技术中多样化的空间组学分辨率使得在更精细层面上准确刻画空间域面临挑战。为此，我们提出了 HyperSTAR，这是一种基于超图的算法，旨在利用空间邻近组织程序之间的高阶关系，在不同分辨率下精准识别空间域。具体而言，我们引入了一个基于基因表达引导的超边分解模块，以优化超图结构并精确描绘空间域边界。此外，我们设计了一个超图注意力卷积神经网络，能够自适应地学习每条超边的重要性，从而增强模型在空间邻近多点位和/或单细胞间捕获复杂高阶关系的能力。HyperSTAR 在揭示组织亚结构、推断时空模式以及去噪空间分辨基因表达等任务中优于现有的图神经网络模型。该方法能够有效处理多种类型的空间组学数据，并可无缝扩展至大规模数据集。该方法成功揭示了乳腺癌切片中的空间异质性，其结果通过独立临床数据的功能与生存分析得到了验证。HyperSTAR 代表了空间组学分析领域的重要进展，提供了一种稳健工具，用于探索不同分辨率与数据类型下的复杂空间模式。其捕获空间邻近点位/细胞间精细高阶关系的能力，使其成为推动生命科学研究，尤其是癌症和发育生物学领域的重要工具。该工具箱可在 https://github.com/Ringoio/HyperSTAR 获取。

### 第二部分 AI 大师评价

该研究提出了一种创新的超图学习框架 HyperSTAR，用于解析不同分辨率下的空间组学数据，通过整合高阶空间关系精确识别组织结构与肿瘤微环境。其核心贡献在于结合基因表达引导的超边分解与注意力卷积网络，从而实现对复杂空间异质性的深度建模。模型在组织亚结构识别及乳腺癌空间异质性分析方面表现优越并具良好泛化性。该工作显著提升了空间组学分析的精细化与可扩展性，但未来仍需进一步验证其在更多组织类型及临床场景中的适用性。

---

速递结束，祝您工作愉快！